Arix Bioscience plc

 

Transaction in own shares

 

LONDON, 18 May 2021: Arix Bioscience plc ("Arix" or "the Company") (LSE:ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces that it purchased the following number of its ordinary shares of 0.001 pence each on the London Stock Exchange from Jefferies International Limited as part of a buyback programme announced on 22 March 2021.

 

Date of purchase	18 May 2021
Aggregate number of shares purchased	75,000
Highest price paid per share	182.50p
Lowest price paid per share	181.10p
Average price paid per share	182.14p

 

Arix intends to retain the purchased shares in treasury.

Following settlement of the above purchase, Arix will have 132,426,800 ordinary shares of 0.001 pence each in issue (excluding 3,182,853 ordinary shares of 0.001 pence each held in treasury). This number represents the total voting rights in Arix and may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.             

In accordance with Article 5(1)(b) of Regulation (EU) No. 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018), the schedule below contains detailed information of the individual trades made by Jefferies International Limited as part of the buyback programme.

[ENDS]

 

For more information on Arix, please contact:

 

Arix Bioscience plc

Charlotte Parry, Head of Investor Relations

+44 (0)20 7290 1072

charlotte@arixbioscience.com

 

 

Optimum Strategic Communications

Mary Clark, Supriya Mathur, Shabnam Bashir

+44 (0)20 3922 1906

optimum.arix@optimumcomms.com

 

 

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

 

 

Transaction Date	Transaction Time	Volume	Price (GBp)	Platform	Transaction Reference Number
18/05/2021	10:26:08	25,000	182.50	London Stock Exchange	00240802771TRLO1
18/05/2021	15:03:57	25,000	182.00	London Stock Exchange	00240875732TRLO1
18/05/2021	15:26:00	2,386	181.10	London Stock Exchange	00240886737TRLO1
18/05/2021	16:35:00	22,614	182.00	London Stock Exchange	00240939921TRLO1